Mucosal and systemic anti-GAG immunity induced by neonatal immunization with HIV LAMP/gag DNA vaccine in mice

Immunobiology

Volumn 216, Issue 4, 2011, Pages 505-512

  Goldoni, Adriana Letícia ^a   Maciel, Milton ^e   Rigato, Paula Ordonhez ^a   Piubelli, Orlando ^a   de Brito, Cyro Alves ^a   Melo, Andrea ^c   Marques, Ernesto Torres ^c,d   August, Joseph Thomas ^b   Duarte, Alberto José da Silva ^a   Sato, Maria Notomi ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c INSTITUTO OSWALDO CRUZ   (Brazil)

^d Center for Vaccine Research   (United States)

^e UNIVERSITY OF MARYLAND   (United States)

Author keywords

DNA vaccines; HIV; Mice; Mucosal; Neonates

Indexed keywords

DNA VACCINE; GAG PROTEIN; GAG VACCINE; GAMMA INTERFERON; HIV LAMP GAG DNA VACCINE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; INTERLEUKIN 4; LYSOSOME ASSOCIATED MEMBRANE PROTEIN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; UNCLASSIFIED DRUG;

ADULT ANIMAL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOTOXIC T LYMPHOCYTE; ENDOSOME; FEMALE; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMORAL IMMUNITY; IMMUNE SYSTEM; IMMUNIZATION; IMMUNOGENICITY; IN VIVO STUDY; INTESTINE; LYMPHOCYTE FUNCTION; LYSOSOME; MALE; MATURATION; MOUSE; MUCOSAL IMMUNITY; NEWBORN; NONHUMAN; NUCLEOTIDE SEQUENCE; PERINATAL PERIOD; PRIORITY JOURNAL; REPEATED DRUG DOSE; SPLEEN; SPLEEN CELL; TH1 CELL; TH2 CELL;

AIDS VACCINES; ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CYTOKINES; DEPENDOVIRUS; FEMALE; GENE PRODUCTS, GAG; HIV ANTIBODIES; HIV INFECTIONS; IMMUNITY, MUCOSAL; IMMUNIZATION; IMMUNOGLOBULIN A, SECRETORY; LYSOSOME-ASSOCIATED MEMBRANE GLYCOPROTEINS; MALE; MICE; MICE, INBRED BALB C; VACCINES, DNA;

EID: 79952192990     PISSN: 01712985     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.imbio.2010.08.007     Document Type: Article

References (34)

1. Adkins B. T-cell function in newborn mice and humans. Immunol. Today 1999, 20:330.
2. Adkins B., Leclerc C., Marshall-Clarke S. Neonatal adaptive immunity comes of age. Nat. Rev. Immunol. 2004, 4:553.
3. Arruda L.B., Sim D., Chikhlikar P.R., Maciel M., Akasaki K., August J.T., Marques E.T. Dendritic cell-lysosomal-associated membrane protein (LAMP) and LAMP-1-HIV-1 gag chimeras have distinct cellular trafficking pathways and prime T and B cell responses to a diverse repertoire of epitopes. J. Immunol. 2006, 177:2265.
4. Arthos J., Cicala C., Martinelli E., Macleod K., Van Ryk D., Wei D., Xiao Z., Veenstra T.D., Conrad T.P., Lempicki R.A., McLaughlin S., Pascuccio M., Gopaul R., McNally J., Cruz C.C., Censoplano N., Chung E., Reitano K.N., Kottilil S., Goode D.J., Fauci A.S. HIV-1 envelope protein binds to and signals through integrin alpha4beta7, the gut mucosal homing receptor for peripheral T cells. Nat. Immunol. 2008, 9:301.
5. Bessis N., GarciaCozar F.J., Boissier M.C. Immune responses to gene therapy vectors: influence on vector function and effector mechanisms. Gene. Ther. 2004, 11(Suppl. 1):S10.
6. Brave A., Hallengard D., Schroder U., Blomberg P., Wahren B., Hinkula J. Intranasal immunization of young mice with a multigene HIV-1 vaccine in combination with the N3 adjuvant induces mucosal and systemic immune responses. Vaccine 2008, 26:5075.
7. Cazac B.B., Roes J. TGF-beta receptor controls B cell responsiveness and induction of IgA in vivo. Immunity 2000, 13:443.
8. Chikhlikar P., de Arruda L.B., Maciel M., Silvera P., Lewis M.G., August J.T., Marques E.T. DNA encoding an HIV-1 Gag/human lysosome-associated membrane protein-1 chimera elicits a broad cellular and humoral immune response in Rhesus macaques. PLoS One 2006, 1:e135.
9. Dadaglio G., Sun C.M., Lo-Man R., Siegrist C.A., Leclerc C. Efficient in vivo priming of specific cytotoxic T cell responses by neonatal dendritic cells. J. Immunol. 2002, 168:2219.
10. Dale C.J., De Rose R., Wilson K.M., Croom H.A., Thomson S., Coupar B.E., Ramsay A., Purcell D.F., Ffrench R., Law M., Emery S., Cooper D.A., Ramshaw I.A., Boyle D.B., Kent S.J. Evaluation in macaques of HIV-1 DNA vaccines containing primate CpG motifs and fowlpoxvirus vaccines co-expressing IFNgamma or IL-12. Vaccine 2004, 23:188.
11. de Arruda L.B., Chikhlikar P.R., August J.T., Marques E.T. DNA vaccine encoding human immunodeficiency virus-1 Gag, targeted to the major histocompatibility complex II compartment by lysosomal-associated membrane protein, elicits enhanced long-term memory response. Immunology 2004, 112:126.
12. De Brito C.A., Goldoni A.L., Notomi-Sato M. Immune adjuvants in early life: targeting the innate immune system to overcome impaired adaptive response. Immunotherapy 2009, 1:883.
13. de Witte L., Bobardt M., Chatterji U., Degeest G., David G., Geijtenbeek T.B., Gallay P. Syndecan-3 is a dendritic cell-specific attachment receptor for HIV-1. Proc. Natl. Acad. Sci. USA 2007, 104:19464.
14. Deml L., Schirmbeck R., Reimann J., Wolf H., Wagner R. Immunostimulatory CpG motifs trigger a T helper-1 immune response to human immunodeficiency virus type-1 (HIV-1) gp 160 envelope proteins. Clin. Chem. Lab. Med. 1999, 37:199.
15. Donnelly J.J., Ulmer J.B., Shiver J.W., Liu M.A. DNA vaccines. Annu. Rev. Immunol. 1997, 15:617.
16. Geijtenbeek T.B., van Kooyk Y. DC-SIGN: a novel HIV receptor on DCs that mediates HIV-1 transmission. Curr. Top. Microbiol. Immunol. 2003, 276:31.
17. Gerdts V., Babiuk L.A., van Drunen Littel-van den H., Griebel P.J. Fetal immunization by a DNA vaccine delivered into the oral cavity. Nat. Med. 2000, 6:929.
18. Gouws E., Stanecki K.A., Lyerla R., Ghys P.D. The epidemiology of HIV infection among young people aged 15-24 years in southern Africa. AIDS 2008, 22(Suppl. 4):S5.
19. Grossman Z., Meier-Schellersheim M., Paul W.E., Picker L.J. Pathogenesis of HIV infection: what the virus spares is as important as what it destroys. Nat. Med. 2006, 12:289.
20. Huber S., Schramm C., Lehr H.A., Mann A., Schmitt S., Becker C., Protschka M., Galle P.R., Neurath M.F., Blessing M. Cutting edge: TGF-beta signaling is required for the in vivo expansion and immunosuppressive capacity of regulatory CD4+ CD25+ T cells. J. Immunol. 2004, 173:6526.
21. Jiang J.Q., Patrick A., Moss R.B., Rosenthal K.L. CD8+ T-cell-mediated cross-clade protection in the genital tract following intranasal immunization with inactivated human immunodeficiency virus antigen plus CpG oligodeoxynucleotides. J. Virol. 2005, 79:393.
22. Kojima Y., Xin K.Q., Ooki T., Hamajima K., Oikawa T., Shinoda K., Ozaki T., Hoshino Y., Jounai N., Nakazawa M., Klinman D., Okuda K. Adjuvant effect of multi-CpG motifs on an HIV-1 DNA vaccine. Vaccine 2002, 20:2857.
23. Kraynyak K.A., Kutzler M.A., Cisper N.J., Khan A.S., Draghia-Akli R., Sardesal N.Y., Lewis M.G., Yan J., Weiner D.B. Systemic immunization with CCL27/CTACK modulates immune responses at mucosal sites in mice and macaques. Vaccine 2010, 28:1942.
24. Lambert A.A., Gilbert C., Richard M., Beaulieu A.D., Tremblay M.J. The C-type lectin surface receptor DCIR acts as a new attachment factor for HIV-1 in dendritic cells and contributes to trans- and cis-infection pathways. Blood 2008, 112:1299.
25. Marques E.T., Chikhlikar P., de Arruda L.B., Leao I.C., Lu Y., Wong J., Chen J.S., Byrne B., August J.T. HIV-1 p55Gag encoded in the lysosome-associated membrane protein-1 as a DNA plasmid vaccine chimera is highly expressed, traffics to the major histocompatibility class II compartment, and elicits enhanced immune responses. J. Biol. Chem. 2003, 278:37926.
26. Mehandru S., Poles M.A., Tenner-Racz K., Horowitz A., Hurley A., Hogan C., Boden D., Racz P., Markowitz M. Primary HIV-1 infection is associated with preferential depletion of CD4+T lymphocytes from effector sites in the gastrointestinal tract. J. Exp. Med. 2004, 200:761.
27. Neurath M.F., Finotto S., Glimcher L.H. The role of Th1/Th2 polarization in mucosal immunity. Nat. Med. 2002, 8:567.
28. Rollman E., Hinkula J., Arteaga J., Zuber B., Kjerrstrom A., Liu M., Wahren B., Ljungberg K. Multi-subtype gp160 DNA immunization induces broadly neutralizing anti-HIV antibodies. Gene Ther. 2004, 11:1146.
29. Rowell J.F., Ruff A.L., Guarnieri F.G., Staveley-O'Carroll K., Lin X., Tang J., August J.T., Siliciano R.F. Lysosome-associated membrane protein-1-mediated targeting of the HIV-1 envelope protein to an endosomal/lysosomal compartment enhances its presentation to MHC class II-restricted T cells. J. Immunol. 1995, 155:1818.
30. Ruff A.L., Guarnieri F.G., Staveley-O'Carroll K., Siliciano R.F., August J.T. The enhanced immune response to the HIV gp160/LAMP chimeric gene product targeted to the lysosome membrane protein trafficking pathway. J. Biol. Chem. 1997, 272:8671.
31. Siegrist C.A. Neonatal and early life vaccinology. Vaccine 2001, 19:3331.
32. UNAIDS, 2008. Report on the global AIDS epidemic 2008. UNAIDS, 1.
33. Valentin A., Chikhlikar P., Patel V., Rosati M., Maciel M., Chang K.H., Silvera P., Felber B.K., Pavlakis G.N., August J.T., Marques E.T. Comparison of DNA vaccines producing HIV-1 Gag and LAMP/Gag chimera in rhesus macaques reveals antigen-specific T-cell responses with distinct phenotypes. Vaccine 2009, 27:4840.
34. Xiang Z., Li Y., Gao G., Wilson J.M., Ertl H.C. Mucosally delivered E1-deleted adenoviral vaccine carriers induce transgene product-specific antibody responses in neonatal mice. J. Immunol. 2003, 171:4287.